AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC
Clinical trial NCT04413201 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04413201
- Sponsor
- Michael Hopp
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-11
- Primary completion
- 2026-12-31
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.